RXSIGHT INC (RXST)
Health Care · Premium intraocular lens devices · NASDAQ
RxSight is the only company commercializing light-adjustable intraocular lenses that let surgeons customize patient vision after cataract surgery, eliminating pre-operative guesswork.
What RXSIGHT INC does
RxSight is a medical technology company that designs and commercializes the RxSight Light Adjustable Lens (LAL) system for cataract surgery. The system consists of a proprietary photosensitive silicone-based intraocular lens (IOL) combined with a Light Delivery Device (LDD) that allows surgeons to customize and adjust a patient's vision after surgery using UV light exposure. Unlike conventional premium IOLs that are fixed-power lenses, the RxSight system enables post-surgical refinement of visual acuity in precise 0.25 diopter increments to optimize each patient's individual vision outcomes.
Themes: ["Premium cataract surgery","Intraocular lens technology","Customized vision correction","Post-surgical refractive adjustment"]
Fundamentals
- Price$5.08 as of 2026-07-09 close
- Market cap$210M as of 2026-07-10
- 1-year return-58.2% as of 2026-07-09 close
- Net margin-36.6% as of 2026-07-10
- Gross margin+77.0% as of 2026-07-10
- ROE-17.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-14.1% as of 2026-07-10
- Revenue CAGR (3y)+40.0% SEC XBRL
- Beta1.16 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- AcrySof (Alcon)
- Tecnis (Johnson & Johnson)
- Panoptix (Alcon)
- Symfony (Johnson & Johnson)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.